A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Inclusion Criteria: * Male or female aged ≥18 years. * Diagnosed with ITP that has persisted for ≥3 months and with a platelet count of \<30 X 109/L measured within 2 days prior to inclusion. * Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab and/or TPO-RA. * If receiving emergency care for ITP, treatment should be stopped \>2 weeks before first dose. * A positive result to the ELISA test to detect antibody against GPIIb/IIIa or GPIIb/IIIa and GPIb/IX within 1 week prior to inclusion. * With normal hepatic and renal functions. * ECOG Performance Status ≤ 2. February 16, 2023 After approval by the Ethics Committee on , subjects no longer require platelet glycoprotein autoantibodies positivity upon enrollment. Exclusion Criteria: * Received any treatment of anti-CD38 antibody drug. * Has been diagnosed with malignancy and/or liver failure, heart failure and renal failure. * Known previous infection or seropositivity for HIV, Hepatitis B, Hepatitis C, Cytomegalovirus, EB virus, Syphilis. * Any clinically overt hemorrhage. * Has been diagnosed with cardiac disease, arrhythmia and/or severe or uncontrollable hypertension * Known pulmonary embolism, thrombosis and/or atherosclerosis. * Has been received allogeneic stem cell transplantation or organ transplantation. * Patients with history of current or past psychiatric disease that might interfere with the ability to comply with the study protocol or g…